- Trial met primary efficacy endpoint at week 12

- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo

- 33% placebo-adjusted improvement in EASI at week 12

- 23% of EVO301 patients achieved IGA 0/1 at week 12

- Company to hold conference call and webcast at 8:30 a.m. ET today

Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domain, achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis (AD). The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.

• No comments yet. Be the first to comment!